Trial Profile
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs Formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms OCEAN
- Sponsors AstraZeneca
- 19 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
- 06 May 2009 Actual end date (1 Apr 2009) and actual patient number (613) added as reported by ClinicalTrials.gov.
- 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.